News Metsera gets $215m for obesity trials, and other financings If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.